Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
Metrics to compare | 217330 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship217330PeersSector | |
---|---|---|---|---|
P/E Ratio | −4.1x | −5.1x | −0.7x | |
PEG Ratio | −0.58 | −0.09 | 0.00 | |
Price/Book | 1.6x | 2.3x | 2.6x | |
Price / LTM Sales | 3.2x | 8.0x | 3.4x | |
Upside (Analyst Target) | - | 0.0% | 37.7% | |
Fair Value Upside | Unlock | 16.0% | 4.1% | Unlock |